Improving Quality of Life in Men and Women With Overweight or Obesity

Noom Inc. (Industry)
Overall Status
Active, not recruiting ID
Anticipated Duration (Months)
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the effect of the Noom Healthy Weight Program, a digital behavior change weight loss intervention, on quality of life as measured both by self-report and objective measures, compared to a waitlist control condition.

Condition or DiseaseIntervention/TreatmentPhase
  • Behavioral: Noom Healthy Weight

Study Design

Study Type:
Actual Enrollment :
370 participants
Intervention Model:
Parallel Assignment
None (Open Label)
Primary Purpose:
Official Title:
Randomized, Controlled Trial of a Weight Loss Intervention in Improving Quality of Life in Men and Women With Overweight or Obesity
Actual Study Start Date :
Apr 15, 2021
Anticipated Primary Completion Date :
Feb 15, 2022
Anticipated Study Completion Date :
Mar 1, 2022

Arms and Interventions

No Intervention: Wait List

Experimental: Noom Healthy Weight

Behavioral: Noom Healthy Weight
Behavioral: Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach. Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.

Outcome Measures

Primary Outcome Measures

  1. Weight [4 months]

    Self Reported

  2. In app engagement measures [4 months]

    Self reported and automatically recorded

  3. Stress [4 months]

    Measured via heart rate variability; Data will be collected with a wearable tracking device (Oura Ring). Heart rate variability (HRV) measures the specific changes in time (or variability) between successive heart beats. The time between beats is measured in milliseconds (ms) and is called an "R-R interval" or "inter-beat interval (IBI).

Secondary Outcome Measures

  1. Self Reported Perceived Stress [4 months]

    Perceived Stress Scale (PSS) Scores ranging from 0-13 would be considered low stress. Scores ranging from 14-26 would be considered moderate stress. Scores ranging from 27-40 would be considered high perceived stress

  2. Sleep Quality [4 months]

    Pittsburgh Sleep Quality Index (PSQI); The 19 self-rated items are combined to form seven "component" scores, each of which has a range of 0-3 points. In all cases, a score of "0" indicates no difficulty, while a score of "3" indicates severe difficulty. The seven component scores are then added to yield one "global" score, with a range of 0-21 points, "0" indicating no difficulty and "21" indicating severe difficulties in all areas.

  3. Sleep Impact [4 months]

    Adult Sickle Cell Quality of Life Measurement (ASCQ-Me); 5 point rating scale ranging from never - always.

  4. Sleep Score [4 months]

    Measured via a wearable health tracking device (Oura Ring). Sleep score consists of: Total sleep time, time in bed, sleep efficiency, and resting heart rate.

  5. Appetite and food craving [4 months]

    Food Cravings Questionnaire-State; he Food Cravings Questionnaire-State (FCQ-S) measures the intensity of momentary food craving. The questionnaire has 15 items and response categories range from 1 = strongly disagree to 5 = strongly agree

  6. Reward-related eating [4 months]

    Reward based eating scale (RED-9); A validated, 9-item index that captures reward-based eating drive as a single factor

  7. Perceived physical and mental health over time [4 months]

    Reported via the Health-related quality of life (HRQoL) survey; A multi-dimensional concept that includes domains related to physical, mental, emotional, and social functioning. It goes beyond direct measures of population health, life expectancy, and causes of death, and focuses on the impact health status has on quality of life. 85 = Very good quality of life. 70 = Good quality of life. 57.5 = Moderately good quality of life.

  8. Depression and anxiety [4 months]

    Depression Anxiety Stress Scales (DASS); The DASS is a 42-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress. Scoring: Normal Depression: 0-9 Anxiety: 0-7 Stress: 0-14 Mild Depression: 10-13 Anxiety: 8-9 Stress: 15-18 Moderate Depression: 14-20 Anxiety: 10-14 Stress: 19-25 Severe Depression: 21-27 Anxiety: 15-19 Stress: 26-33 Extremely severe Depression: 28+ Anxiety: 20+ Stress: 34+

Other Outcome Measures

  1. COVID status [4 months]

    COVID health questionnaire

Eligibility Criteria


Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  • Able to understand and provide informed consent

  • 18-65 years old

  • Self-report of good health (physical and mental)

  • Not diagnosed with diabetes

  • Overweight or obesity (BMI ≥ 25)

  • Able to meet our criteria of adherence to the program (at least 1 engagement per week on one of the following: logged exercise, logged meals, steps, weigh-ins, coach messages, read articles, and days with at least one weigh-in.)

  • For females

  • Not within the 6 months postpartum time frame

  • Not planning to become pregnant in the next 5 months.

Exclusion Criteria:
  • Inability or unwillingness of a participant to give written informed consent

  • Currently taking medication which affects sleep or heart rate (e.g., (i) central nervous system stimulants, (ii) respiratory medications, (iii) antihistamines, (iv) central acting hormones (e.g. corticosteroids, thyroid), (v) high-dose anticholinergics, (vi) and cannot be using the maximum recommended dose for antihypertensive medications or use of multiple antihypertensive medications)

  • Current diagnosed mental health condition (except mild anxious or depressive symptoms)

  • Current diagnosed sleep disorder or condition not related to obesity (e.g., narcolepsy)

  • Currently pregnant or ≤ 6 months postpartum

  • Currently participating in shift work and/or have travelled between time zones in the last month

  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the quality of the data; E.g., evidence of an eating disorder, major chronic condition

Contacts and Locations


SiteCityStateCountryPostal Code
1NoomNew YorkNew YorkUnited States10001

Sponsors and Collaborators

  • Noom Inc.


None specified.

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Noom Inc. Identifier:
Other Study ID Numbers:
  • 00048812
First Posted:
May 4, 2021
Last Update Posted:
Nov 18, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 18, 2021